Japan Pharma Regulatory Calendar

Next 90 days

Fixed dates (committee meetings, price changes with an official effective date) and estimated windows (approvals, NHI price listings, meetings not yet announced). Estimated windows come from past intervals and are not official dates. The free page shows every event; the exact window and ticker symbols are shown for the first 3 examples.

Confidence: confirmed = date published by MHLW/Chuikyo; high/medium = estimated from a published approval or committee date and past intervals; low = estimated from last year's meeting calendar. Tickers identify the Japanese marketing authorisation holder or the licensor; they are not a recommendation.

Subscriber edition: sample rows

All columns for a few rows, as in the subscriber edition: estimated window with the method, licensor / partner, ticker symbols and the factual alert that goes out when the official document is published.

How long each step takes (2024–2026 data)

Each new-drug approval in PMDA's list was matched by brand name to the agenda of the MHLW committee that deliberated (審議) or received a report (報告) on it; each NHI listing was taken from Chuikyo's new-drug pricing sheets, which state the approval and listing dates.

Backtest: for every past case we built the p10–p90 window only from cases whose outcome was already known on that date, then checked whether the actual date fell inside. Committee → approval: 281 of 345 (81%; 82% counted once per meeting). Approval → listing: 82 of 111 (74%); the expected listing month (the usual month for approvals made in the same month) was right 57 of 67 times (85%). Misses are mostly products whose listing was postponed well past 90 days.